Method development and validation for determination of antihemolytic activity of eculizumab (Soliris)
- Authors: Prudnikova E.Y.1, Poroshin G.N.1, Kudina N.K.1, Lyagoskin I.V.1, Sazonova E.V.1, Vishnevskiy A.Y.1, Abbasova S.G.1
-
Affiliations:
- International Biotechnology Center «Generium»
- Issue: Vol 4, No 6 (2016)
- Pages: 54-71
- Section: Articles
- URL: https://journals.rcsi.science/2307-9266/article/view/111470
- DOI: https://doi.org/10.19163/2307-9266-2016-4-6-54-71
- ID: 111470
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
E. Yu. Prudnikova
International Biotechnology Center «Generium»
Email: prudnikova@ibcgenerium.ru
G. N. Poroshin
International Biotechnology Center «Generium»
Email: poroshin@ibcgenerium.ru
N. K. Kudina
International Biotechnology Center «Generium»
Email: kudina@ibcgenerium.ru
I. V. Lyagoskin
International Biotechnology Center «Generium»
Email: lyagoskin@ibcgenerium.ru
E. V. Sazonova
International Biotechnology Center «Generium»
Email: sazonova@ibcgenerium.ru
A. Yu. Vishnevskiy
International Biotechnology Center «Generium»
Email: vishnevskiy@ibcgenerium.ru
S. G. Abbasova
International Biotechnology Center «Generium»
Email: abbasova@ibcgenerium.ru
References
- ГОСТ Р 52249-2009 «Правила производства и контроля качества лекарственных средств».
- Findlay J.W.A., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., Khan M.N., Bowsher R.R. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. Journal of Pharmaceutical and Biomedical Analysis. 2000, N. 21, рр. 1249-1273.
- Assay Validation Methods – Definitions and Terms. Available from: http://www.fws.gov/aah/PDF/QI-Terms%20and%20Defs.pdf
- Hill A., Rother R. P., Arnold L., Kelly R., Cullen M.J., Richards S.J., Hillmen P. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica April. 2010, N. 95, рр. 567-573.
- Johnson R., Hillmen P. Johnson, R. Paroxysmal nocturnal haemoglobinuria: Nature’s gene therapy? J Clin Pathol. 2002, N. 55(3), рр.145−52.
- Parker C.1., Omine M., Richards S., Nishimura J., Bessler M., Ware R., Hillmen P., Luzzatto L., Young N., Kinoshita T., Rosse W., Socié G. International PNH Interest Group. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005, N. 106 (12), рр. 3699-709.
- Hillmen P., Hall C., Marsh J., Elebute M., Bombara M.P., Petro B.E., Cullen M.J., Richards S.J., Rollins S.A., Mojcik C.F., Rother R.P. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria . N Engl J Med. 2004,
- N. 350 (6). рр. 552−9.
- Rother R.P., Rollins S.A., Mojcik C.F., Brodsky R.A., Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria . Nat Biotech. 2007, N. 25 (11), рр. 1256–64.
- Scientific discussion. Available from: h ttp ://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000791/WC500054212.pdf
- Guideline on bioanalytical method validation: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
- A Step-by-Step Approach to Establishing a Method Validation Program: http://www.ivtnetwork.com/sites/default/files/A%20Step%20by%20Step%20Approach%20to%20Establishing%20a%20Method%20Validation%20Program.pdf
- Hohensteina A., Hebella M., Zikryb H. Development and validation of a novel cell-based assay for potencydetermination of human parathyroid hormone (PTH). Journal of Pharmaceutical and Biomedical Analysis. 2014, N. 98, рр. 345-350.